Medical/Pharmaceuticals
YolTech Therapeutics to Initiate a Clinical Trial for YOLT-204, a First-in-Class Bone Marrow-Targeted In Vivo Gene Editing Therapy for β-Thalassemia
SHANGHAI, Jan. 20, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial forYOLT-204, an investigational therapy for the treatment of transfusion-dependent beta-thalassemia (TDT). TDT i...
2025-01-21 10:34
2978
CARsgen's Allogeneic CD38 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial
SHANGHAI, Jan. 20, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that KJ-C2320, an allogeneic CAR T-cell therapy targeting CD38, has a...
2025-01-20 21:50
3137
Hanwha Life Launches 'Mobile Family Center' in Indonesia to Strengthen Community-Centered Mental Health Support for Women and Children
* Following the launch of "Digital Family Center" last year, "Mobile Family Center" is now open * Provides on-site psychological and self-reliance counseling for women and children facing difficulties at home * Over a decade of consistent family-focused social contribution activities, build...
2025-01-17 21:00
9140
Senaparib Approved by NMPA for 1L Maintenance Therapy in Ovarian Cancer
SHANGHAI, Jan. 16, 2025 /PRNewswire/ -- IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, is pleased to announce that Senaparib Capsules (派舒宁®）has received marketing authorizatio...
2025-01-17 10:56
2622
LOTTE BIOLOGICS to Present at the 2025 J.P. Morgan Healthcare Conference
* New CEO James Park Delivers First Presentation at J.P. Morgan Healthcare Conference on "Advancing as a Global CDMO Leader" * Unveiling of Next-Generation ADC Platform 'SoluFlex Link': Enabling High-Potency, High-Yield ADC Development and Manufacturing * Incheon Songdo Bio Campus Plant 1 Un...
2025-01-17 07:11
4458
Hong Kong Pharma Digital Technology Holdings Limited Announces Closing of Initial Public Offering
NEW YORK, Jan. 16, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited ("Hong Kong Pharma" or the "Company") (NASDAQ: HKPD), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services inHong Kong, today announced the closing o...
2025-01-17 03:10
4066
Shanghai opens its doors to foreign-owned hospitals
SHANGHAI, Jan. 14, 2025 /PRNewswire/ -- A news report from
english.shanghai.gov.cn
2025-01-16 09:39
2827
(Taiwan) CMU Healthcare System and Nobel Laureate Randy Schekman Drive New Frontiers in Exosome Technology
TAICHUNG, Jan. 15, 2025 /PRNewswire/ -- On November 2, 2024, China Medical University (CMU) and Healthcare System hosted the International Forum of Extracellular Vesicles Technology and Novel Therapeutics to highlightTaiwan's advancements and explore new horizons in biomedical applications.Profes...
2025-01-16 09:00
2776
NEXTBIOMEDICAL Receives IDE Approval from FDA for Nexsphere-F™, an Embolic Microsphere for Use in Genicular Artery Embolization (GAE) for Knee Osteoarthritis: The U.S. RESORB Trial Launches
SEOUL, South Korea, Jan. 15, 2025 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD, a KOSDAQ-listed innovative medical device company inSouth Korea, proudly announced that it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for its clinical tria...
2025-01-15 22:00
3632
Celltrion unveils strategic vision for advancing its innovative drug pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
* Celltrion unveils strategic roadmap for the first time outlining its innovative drug development strategy and its plan to submit 13 Investigational New Drug (IND) application by 2028 * Company reinforces its commitment to a two-pillar growth strategy focusing on its groundbreaking new drug ...
2025-01-15 10:52
2789
Hong Kong Pharma Digital Technology Holdings Limited Announces Pricing of Initial Public Offering
NEW YORK, Jan. 14, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited ("Hong Kong Pharma" or the "Company"), a leading provider of OTC pharmaceutical cross-border e-commerce supply chain services inHong Kong, today announced the pricing of its initial public offering (the "...
2025-01-15 02:01
2054
South Korea's WIRobotics Takes the Spotlight at CES 2025, Plans Global Expansion
YONGIN, South Korea, Jan. 14, 2025 /PRNewswire/ -- WIRobotics, the company behind the revolutionary wearable mobility solutionWIM(We Innovate Mobility), has achieved a major milestone at CES 2025, one of the world's premier technology trade shows. Featuring more than 4,500 companies from 166 coun...
2025-01-15 01:00
3224
ImmunoForge Receives IND Approval for Phase 2 Clinical Trial of 'Pemziviptadil' for DMD Cardiomyopathy Treatment from FDA, and KF1601, a chronic myeloid leukemia treatment, phase 1 clinical trial IND approved by MFDS
SEOUL, South Korea, Jan. 14, 2025 /PRNewswire/ -- ImmunoForge announced that it has received approval for the Phase 2 clinical trial IND for 'Pemziviptadil (development code name PF1804),' a treatment for DMD (Duchenne Muscular Dystrophy) cardiomyopathy, from the U.S. Food and Drug Administration...
2025-01-14 21:00
2886
Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currentl...
2025-01-13 22:05
3449
Neuromodulation Wristband ObeEnd Reduces Heart Rate and Perceived Exercise Exertion
VANCOUVER, BC, Jan. 13, 2025 /PRNewswire/ -- WAT Medical Enterprise collaborated withConcordia University and Mitacs Canada to conduct a study using ObeEnd, the neuromodulation device designedby WAT for weight and health management. The study revealed that electroacupuncture may help improve exe...
2025-01-13 22:00
2401
CARsgen's Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial
SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that KJ-C2219, an allogeneic CAR T-cell therapy targeting CD19/CD20, ...
2025-01-13 21:50
2146
WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative (PSCI)
SHANGHAI, Jan. 12, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences industries, announced that it has joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Suppl...
2025-01-13 08:00
3214
Regor Releases Phase 2a Topline Results for RGT-075, an Oral Once-daily Small Molecule GLP-1R Agonist, and Begins Phase 2b Study in the US for the Treatment of Obesity
* Regor announced its 12-week single-dose Phase 2a trial results for RGT-075, a once-daily oral GLP-1RA, reporting 5% placebo-adjusted weight-loss with no plateau * No treatment-related severe adverse events (AEs), with only 4% discontinuation rate due to AEs, same as placebo * Enrollment o...
2025-01-11 01:30
3069
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
* This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and which advanced rapidly into the clinical phase. * Under the agreement, M...
2025-01-10 22:00
2807
Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immuno...
2025-01-10 21:01
4805
Week's Top Stories
Most Reposted
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 319 media titles]
2026-02-16 10:00
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 318 media titles]
2026-02-19 14:30
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 277 media titles]
2026-02-17 19:12
Kung Fu Meets Spring -- Unitree Spring Festival Gala Robots Present "Cyber Real Kung Fu" in the Year of the Horse
[Picked up by 256 media titles]
2026-02-17 14:16SMU MBA Rises in FT Global Rankings, Excelling in ESG, Salary and Value-for-Money
[Picked up by 250 media titles]
2026-02-16 08:00Most Read
From Date Night to Game Night: Shop Nework's Special Valentine's Deal to Share the Meaningful Moments and Memories
2026-02-15 01:00
6501
